Why is ovarian cancer often found late?

Ovarian epithelial, fallopian tube, or peritoneal cancer may not cause early signs or symptoms. When signs or symptoms do appear, the cancer is often advanced.

Three separate things line up to produce that pattern, and it helps to see them one at a time.

The ovaries sit deep in the pelvis. There is loose space around them. A growth can enlarge for a long while without pressing on anything that produces a clear, sharp warning.

The symptoms it does cause are ordinary ones. Pain, swelling, or a feeling of pressure in the abdomen or pelvis. A sudden or frequent urge to urinate. Trouble eating or feeling full quickly. A lump in the pelvic area. Gas, bloating, or constipation. Every one of those is far more often caused by something harmless. Both patients and doctors reasonably think of other explanations first.

There is no screening test that works. This is the biggest reason, and it surprises people who assume a yearly blood test exists.

Why there is no ovarian cancer screening

The U.S. Preventive Services Task Force recommends against screening for ovarian cancer in women without symptoms. That is a grade D recommendation, meaning the harms outweigh the benefits.

The two obvious candidates have been tested and failed. The CA-125 blood test and transvaginal ultrasound are both used to evaluate women who already have symptoms. Used as screening tests, neither reduces deaths from ovarian cancer.

They do cause harm. Across screening rounds, false-positive rates ran from 4.2% to 44.2%. Between 0.2% and 3.25% of women screened had surgery to investigate a positive result and turned out not to have cancer. Up to 15% of those women had major surgical complications. Removing healthy ovaries because a test was wrong is a real cost, not a theoretical one.

One exclusion matters enormously. That recommendation covers women at average risk without symptoms. It does not apply to women with a known hereditary cancer syndrome, and it does not apply to anyone with symptoms.

What the numbers look like

For 2026 the American Cancer Society projects 21,010 new ovarian cancer cases and 12,450 deaths, a forecast SEER, the federal cancer statistics program, republishes. The median age at diagnosis is 63.

About 54% are found only after the cancer has spread to distant sites. In the group diagnosed from 2016 through 2022, five-year relative survival is 52.0% overall. By stage it is 91.9% when the cancer is still confined to the ovary, 70.1% once it has reached nearby tissue or nodes, and 31.5% once it has spread further. The gap between the first and last figure is why the timing question matters so much.

What you can actually do

Since screening is not an option, symptoms are the signal. The pattern to act on is new, persistent, and unlike your normal. Bloating, pelvic pressure, feeling full fast, or urinary urgency that shows up most days and lasts more than a few weeks deserves a visit, not a wait-and-see.

Say the words out loud at that visit: "I would like to rule out ovarian cancer." That single sentence changes what gets ordered. Appropriate evaluation may include a pelvic exam, transvaginal ultrasound, a CA-125 blood test, and a CT scan.

If ovarian or breast cancer runs in your family, or if a first-degree relative had ovarian cancer, ask for genetic counseling. Inherited changes in the BRCA1 or BRCA2 genes raise ovarian cancer risk sharply, and carriers have surveillance and risk-reducing options that average-risk women do not.